Literature DB >> 28845232

Solifenacin linked QT interval prolongation and torsades de pointes.

Jonathan J H Bray1, Jules C Hancox2.   

Abstract

Entities:  

Year:  2017        PMID： 28845232      PMCID： PMC5564888          DOI： 10.1177/2042098617702616

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN： 2042-0986


× No keyword cloud information.
  17 in total

1.  QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman.

Authors:  Hiroshi Asajima; Yohei Sekiguchi; Shoji Matsushima; Naotaka Saito; Takahiko Saito
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

2.  [Case Report; A case of QT prolongation and torsade de pointes associated with Solifenacin].

Authors:  Fumina Yoshida; Yasuo Okusu; Atsushi Wada; Yoshitaka Hiroe; Hideto Yano; Takahiro Miyazaki; Hiroyuki Ishikawa; Masashi Nakamura; Takatoshi Mochizuki
Journal:  Nihon Naika Gakkai Zasshi       Date:  2014-11-10

3.  Use of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Haoyu Zeng; Maria I Roman; Edward Lis; Armando Lagrutta; Frederick Sannajust
Journal:  J Pharmacol Toxicol Methods       Date:  2016-05-21       Impact factor: 1.950

4.  Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).

Authors:  Paul Abrams; Con Kelleher; David Staskin; Tomasz Rechberger; Richard Kay; Reynaldo Martina; Donald Newgreen; Asha Paireddy; Rob van Maanen; Arwin Ridder
Journal:  Eur Urol       Date:  2014-02-19       Impact factor: 20.096

Review 5.  Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.

Authors:  Peter J Schwartz; Raymond L Woosley
Journal:  J Am Coll Cardiol       Date:  2016-04-05       Impact factor: 24.094

6.  Evaluation of a QT nomogram for risk assessment after antidepressant overdose.

Authors:  W Stephen Waring; Ann Graham; Julie Gray; Allen D Wilson; Catherine Howell; D Nicholas Bateman
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

7.  Clinical electrophysiology, efficacy and safety of chronic oral cibenzoline therapy in refractory ventricular tachycardia.

Authors:  S T Rothbart; S Saksena
Journal:  Am J Cardiol       Date:  1986-04-15       Impact factor: 2.778

Review 8.  Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram.

Authors:  A Chan; G K Isbister; C M J Kirkpatrick; S B Dufful
Journal:  QJM       Date:  2007-09-19

9.  The electrophysiologic effects of oral cibenzoline.

Authors:  M Kushner; E Magiros; R Peters; N Carliner; G Plotnick; M Fisher
Journal:  J Electrocardiol       Date:  1984-01       Impact factor: 1.438

Review 10.  The hERG potassium channel and hERG screening for drug-induced torsades de pointes.

Authors:  Jules C Hancox; Mark J McPate; Aziza El Harchi; Yi Hong Zhang
Journal:  Pharmacol Ther       Date:  2008-06-18       Impact factor: 12.310
View more
  1 in total

1.  Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases.

Authors:  Michael Hecker; Niklas Frahm; Paula Bachmann; Jane Louisa Debus; Marie-Celine Haker; Pegah Mashhadiakbar; Silvan Elias Langhorst; Julia Baldt; Barbara Streckenbach; Felicita Heidler; Uwe Klaus Zettl
Journal:  Front Pharmacol       Date:  2022-08-05       Impact factor: 5.988
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.